Custom service

VHH Antibody Production

Single-domain binders from camelid heavy-chain antibodies.

Size: ~15 kDa — single domain, no light chainTimeline: 10–14 weeks — to recombinant VHHStability: >80 °C — reversible refolding

Camelids produce a class of antibody that lacks light chains entirely. Its antigen-binding domain — the VHH, or nanobody — is a single 15 kDa immunoglobulin fold that binds antigen with an affinity comparable to a conventional Fab, while remaining stable at temperatures that destroy most proteins and folding correctly after extraction from a reducing environment.

The small size reaches epitopes that conventional antibodies cannot. Clefts, active sites and buried loops that are sterically shielded from a 150 kDa IgG are accessible to a VHH, which is why these reagents dominate work on enzyme active sites, G protein-coupled receptor binding pockets and viral neutralisation sites. The same property makes them easy to format: dimers, biparatopic constructs, enzyme fusions and immobilised capture reagents all remain functional.

Production begins with immunisation of a llama or alpaca, followed by construction of a VHH phage display library from peripheral blood lymphocytes. Panning against the immobilised antigen enriches binders over three rounds, and positive clones are sequenced, expressed in E. coli or yeast, and characterised. Because the sequence is short and single-domain, downstream engineering — humanisation, affinity maturation, multimerisation — is straightforward.

Service Highlights

Where it fits

VHHs are the format of choice for structural biology, for assays requiring a small capture reagent, and for applications where stability matters — in vivo imaging, oral or inhaled delivery, and reagents that must survive shipping without a cold chain. Biparatopic constructs also make them attractive for receptor clustering.

The limitation is access: llama and alpaca immunisation is slower and more expensive than a mouse campaign, and a synthetic VHH library is an alternative when no animal work is possible. For simple ELISA reagents the cost per binder is higher than a conventional monoclonal.

Documentation and QC

Each VHH is delivered with sequence, expression yield, SDS-PAGE and SEC-HPLC purity, affinity by BLI or SPR, and a thermal stability curve. Endotoxin is measured for any construct intended for in vivo use, and the expression plasmid is supplied for in-house production.

Frequently asked questions

Can a VHH replace an antibody in an existing assay?

Often, but the detection system must change — a 15 kDa domain requires an anti-VHH or anti-tag secondary rather than an anti-species IgG. Sandwich assays usually need a matched pair, and we screen for non-competing pairs on request.

How stable are they really?

Most VHHs withstand 80 °C for an hour and refold after denaturation. That is a general property of the fold, not a guarantee for every clone, so stability is measured per clone rather than assumed.

Do you offer humanised VHHs?

Yes. Framework resurfacing to human VH3 germline typically preserves affinity within two-fold, and the CDRs remain untouched.

Send the antigen and describe the format you need. If the target is a small cleft or an enzyme active site, a VHH is likely the only format that will reach it — and we will confirm that before immunisation.

Service Highlights

  • Single-domain format. 15 kDa, no light chain, no pairing problem, and expression in E. coli at 10–50 mg/L.
  • Cryptic epitope access. Binds active sites, receptor pockets and concave surfaces that a conventional antibody cannot reach.
  • Thermal and chemical stability. Retains binding after incubation at 80 °C and refolds after guanidinium denaturation.
  • Phage display library. Library size 10⁷–10⁸ from a single immunised animal, with three rounds of panning and periplasmic expression screening.
  • Humanisation available. Framework resurfacing to human VH3 germline with CDR retention, typically preserving affinity within two-fold.
  • Multimer formats. Bivalent, biparatopic, Fc-fused and alkaline phosphatase-fused constructs produced to order.

How the work runs

  1. Antigen and animal preparation

    Antigen quality and dose are agreed, and a llama or alpaca is immunised with 100–200 µg per dose over four to six injections.

  2. Library construction

    PBMC are collected, RNA extracted, VHH genes amplified with framework-specific primers, and cloned into a phagemid vector for display.

  3. Panning

    Three rounds against immobilised antigen, with increasing stringency and negative selection on carrier-only surfaces.

  4. Screening

    Periplasmic extracts are tested by ELISA against the target and a control; positives are sequenced and grouped by CDR3 length and sequence.

  5. Expression and purification

    Selected clones expressed in E. coli, purified by His-tag or protein A when an Fc fusion is used, and endotoxin-tested.

  6. Characterisation and formatting

    Affinity by BLI or SPR, thermal stability by nanoDSF, and reformatting to dimer, Fc fusion or conjugate as required.

Specifications & timeline

Size
~15 kDa — single domain, no light chain
Timeline
10–14 weeks — to recombinant VHH
Stability
>80 °C — reversible refolding
Host
Llama or alpaca, immunised under an approved protocol
Library size
10⁷–10⁸ transformants per campaign
Expression host
E. coli (periplasmic), Pichia pastoris for larger quantities
Affinity
Typically 10⁻⁸–10⁻¹⁰ M from an immunised library
Timeline
10–14 weeks including immunisation, panning and expression
Deliverables
Sequence, 1–10 mg purified VHH, affinity and stability data, expression plasmid

Related Products

Next step

Tell us the target, we will tell you what is feasible

Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.